CGA and B-cell chronic lymphocytic leukemia: Interestingly, when we treated mice with a 30-fold higher dose of full-length CgA (10 μg/day) no significant effects were observed (Supplemental Figure 2A-2E), suggesting that CgA can affect CLL progression with a biphasic dose-response curve.